Preoperative Biochemical Predictors of Outcome in Patients With Hip Fracture

Can Biochemical Tests Predict Outcome in Patients With Hip Fracture?

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01280253

Enrollment

999

Registered

2011-01-20

Start date

2011-01-31

Completion date

Unknown

Last updated

2016-11-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip Fracture

Keywords

Predictor, outcome, biochemical

Brief summary

The objective of the study is to identify biochemical predictors of morbidity and mortality in patients suffering from hip fracture. For this purpose blood samples are collected prehospitally or in the emergency department in patients with a suspected hip fracture. During the hospital stay medical history, anesthesiological management recorded. In addition, american society of anesthesiology physiological score (ASA), revised cardiac risk index (RCRI), and POSSUM score is calculated. Morbidity and mortality is recorded in house, after 30 days, after 4 months and after 1 year. Biochemical predictors of outcome will be evaluated with logistic regression analysis. Biochemical predictors include pro-brain natriuretic peptide, lactate, pro-calcitonin, adrenomedullin, copeptin, cystatin c. The predictive value of the potential markers will be compared to that of ASA, RCRI and POSSUM.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients presenting with out of hospital hip fracture at University Hospital Lund Sweden * Informed consent * Blood sampling within 3 hrs of first contact with healthcare

Exclusion criteria

* No consent can be obtained * Non-operative management * Followup through the Swedish National Quality for Hip fracture patients not possible * High energy trauma

Design outcomes

Primary

Measure	Time frame
Mortality	30 days

Secondary

Measure	Time frame	Description
Morbidity	30 day	Infectious complications Cardiovascular complications Thromboembolic complications Respiratory complications Renal complications Surgical complications

Countries

Sweden

Outcome results